Pharmaceutical company $550 million preferred equity acquisition financing

Davis Polk advised the investors in the purchase of $550 million of preferred stock issued by a pharmaceutical manufacturer. The proceeds of the preferred equity financing, together with the proceeds of credit facilities provided by certain financial institutions, were used to finance a portion of a leading private equity group’s acquisition of a majority stake in the pharmaceutical manufacturer.

The Davis Polk finance team included partner Zachary R. Frimet and associates David Waldman, David J. Kilduff, Daniel Feit and Anarelis Ramirez. All members of the Davis Polk team are based in the New York office.